AICAR (Acadesine): An AMPK-Activating Exercise Mimetic for Endurance and Metabolism

This content is provided by Superpower Health for educational and informational purposes only. AICAR (acadesine) is not FDA-approved for any therapeutic indication and is not available through Superpower or through any legitimate prescription channel for fitness, metabolic, or performance use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

The idea of separating the metabolic benefits of endurance exercise from exercise itself has circulated in physiology for decades. Every lap, every mile, every sustained effort reconfigures the cell at the molecular level: mitochondria proliferate, fuel-switching improves, and the metabolic machinery becomes more efficient. The question researchers have long asked is whether any of that reconfiguration is pharmacologically replicable. AICAR was one of the first compounds to suggest the answer might be yes. It is not FDA-approved. It is not available by prescription for performance or metabolic use. It has been prohibited in competitive sport since 2009. What it has done is clarify, with more precision than almost any other molecule, how the cellular energy sensor AMPK operates and what happens when you force it on.

Here is what AICAR is, how its mechanism works at the molecular level, what preclinical and limited human trial data have found, and what the regulatory and anti-doping landscape looks like.

Key Takeaways

• Regulatory Status: Not FDA-approved for any indication. Acadesine was studied in Phase 3 cardiovascular trials in the 1990s and Phase I/II oncology trials in the 2000s; none resulted in approval. Not available by prescription for fitness or metabolic use.
• Research Stage: Human data limited to cardioprotection and hematologic oncology trials. No completed human efficacy trials for endurance, exercise performance, or metabolic optimization have been published as of April 2026.
• Availability: Not available through Superpower, by prescription, or through compounding for performance use. Gray-market material sold online as a research chemical is uncontrolled and carries unknown safety risks.
• Prescribing information: No FDA label exists. For compound reference, see the PubChem monograph for acadesine (CID 378611).
• How it works: Converts intracellularly to ZMP, an AMP analog that activates AMPK, the cellular energy sensor governing mitochondrial biogenesis, glucose uptake, and fat oxidation.
• What research shows: In a landmark 2008 mouse study by Narkar, Downes, and colleagues in Cell, AICAR alone increased running endurance by 44% in sedentary mice through AMPK–PPARδ pathway activation. No equivalent human data exists for performance applications.

AICAR sits at a specific intersection: a compound with rigorous mechanistic science, compelling preclinical data, a failed clinical development history, and a WADA prohibition that reflects how seriously regulators take its performance-enhancement potential. That combination makes it worth understanding precisely, without overstating what the evidence actually supports in humans.

What AICAR Is

AICAR is the abbreviated name for 5-aminoimidazole-4-carboxamide ribonucleoside, also known by its pharmaceutical name acadesine and the experimental code AICA-riboside. It is a nucleoside analog — a synthetic compound structurally related to adenosine — not a peptide. Searches connecting it to the peptide category reflect its prominence in performance research circles, but its mechanism and pharmacology are those of a small-molecule nucleoside. Early characterization work by Winder in a 2000 paper in Diabetes Technology and Therapeutics established that AICAR is an adenosine analog that activates AMP-activated protein kinase (AMPK) in skeletal muscle through conversion to an intracellular AMP mimetic.

The compound was originally developed not for fitness applications but for cardioprotection during coronary artery bypass graft (CABG) surgery, where adenosine regulation was hypothesized to reduce ischemic injury. That clinical program — conducted in the 1990s by Mangano and colleagues in a series of international multicenter trials — found cardiovascular benefits in some populations but failed to meet primary endpoints broadly enough to secure FDA approval. AICAR subsequently attracted renewed attention from metabolic and exercise researchers when the AMPK literature matured enough to suggest its downstream effects might be far broader than cardiac protection alone.

How AICAR Works

Conversion to ZMP and the AMP-mimetic mechanism

When AICAR enters a cell, it is phosphorylated by adenosine kinase to form AICA-ribonucleotide, known as ZMP. A 2006 study by Beckers and colleagues in Molecular Cancer Therapeutics characterized how ZMP is structurally analogous to AMP and accumulates intracellularly in a way that mimics a state of energetic stress. AMPK responds to the AMP-to-ATP ratio: when that ratio rises, as it does during sustained exercise or cellular energy depletion, AMPK activates. ZMP mimics this signal pharmacologically without actual energy depletion having occurred. A foundational 2012 review by Hardie, Ross, and Hawley in Nature Reviews Molecular Cell Biology established AMPK as the master regulator of cellular energy homeostasis, coordinating responses to nutrient deprivation, exercise, and metabolic stress through phosphorylation of downstream targets governing glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. A 2018 Cell Metabolism paper by Lin and Hardie further detailed how AMPK senses glucose and cellular energy, providing context for the upstream signal AICAR reproduces. A 2014 Cell Metabolism review by Hardie mapped out AMPK's crosstalk with other signaling networks relevant to any pharmacological activator of this pathway.

AMPK activation and skeletal muscle metabolism

In skeletal muscle, AMPK activation produces effects that parallel the metabolic adaptations of endurance training. A 2002 study by Sakoda, Ogihara, and colleagues in the American Journal of Physiology Endocrinology and Metabolism demonstrated that AICAR-stimulated AMPK activation is essential for GLUT4-mediated glucose uptake in skeletal muscle, a mechanism distinct from insulin signaling. A 2010 study by Leick, Fentz, and colleagues in the same journal used PGC-1α knockout mice to show that repeated AICAR treatment increased GLUT4 and cytochrome c protein expression in white muscle of wild-type but not PGC-1α-knockout animals, establishing PGC-1α as required for AICAR-induced mitochondrial protein accumulation — although hexokinase II responded similarly in both genotypes, indicating the requirement is pathway-selective rather than universal. A separate 2010 study by McConell, Ng, and colleagues in the Journal of Applied Physiology identified nitric oxide synthase as a central mediator of AICAR- and caffeine-induced mitochondrial biogenesis in L6 myocytes; NOS inhibition attenuated AICAR-induced increases in cytochrome c oxidase (COX)-1 and COX-4 protein expression without affecting AMPK phosphorylation, while the nitric oxide donor SNAP independently reproduced the biogenesis response. Viscomi, Bottani, Civiletto, and colleagues, publishing in Cell Metabolism in 2011, extended this work by demonstrating in three recombinant mouse models of COX deficiency (Surf1 knockout, Sco2 knockout/knockin, and muscle-restricted Cox15 knockout) that AICAR treatment partially corrected cytochrome c oxidase deficiency via the AMPK–PGC-1α axis and normalized motor performance in Sco2 KO/KI animals within 3 weeks of treatment — a preclinical proof-of-concept for AMPK activation in mitochondrial disease, although these findings have not been replicated in humans. Together, these mechanisms converge on what the landmark Narkar study demonstrated behaviorally: sedentary mice receiving AICAR ran 44% further than controls, with gene expression profiles resembling trained muscle.

The Narkar et al. 2008 study: the "exercise in a pill" finding

The paper that moved AICAR from a pharmacology niche to mainstream performance science was published in Cell in 2008 by Narkar, Downes, Yu, and colleagues from the Evans laboratory at the Salk Institute. The study administered AICAR 500 mg/kg/day subcutaneously for four weeks to sedentary C57BL/6J mice (n = 15–20 per group in the endurance cohort) and then assessed running endurance on a treadmill. AICAR-treated mice showed a 44% increase in running time compared with controls (p < 0.05), alongside upregulation of genes governing oxidative metabolism in skeletal muscle — consistent with a shift toward slow-twitch, fat-oxidizing fiber characteristics. The study also combined AICAR with the PPARδ agonist GW501516 (5 mg/kg/day) and reported synergistic effects, with the combination producing approximately 68–75% gains in endurance depending on the metric. The AMPK–PPARδ axis was identified as the critical pathway. This paper directly triggered WADA scrutiny and the 2009 prohibition on AICAR in competitive sport. The findings have not been replicated in humans.

Effects on fat metabolism and insulin sensitivity

Beyond endurance, AICAR's AMPK activation has preclinical implications for metabolic health. A 2002 study by Buhl and colleagues in Diabetes treated obese Zucker (fa/fa) rats (n = 6 per AICAR and control groups, n = 8 lean controls) with subcutaneous AICAR 0.5 mg/g body weight daily for 7 weeks and reported a 14.6 ± 4.3 mmHg reduction in systolic blood pressure (p < 0.05), normalized oral glucose tolerance, reduced triglycerides and free fatty acids (p < 0.01 vs. ad libitum controls), increased HDL cholesterol (p < 0.01), and enhanced skeletal muscle GLUT4 expression with improved insulin-stimulated glucose transport. The very small per-group cohort and the obese-Zucker model limit direct extrapolation to humans, but the metabolic profile is representative of AICAR's preclinical signature. A 2010 study by Sajan and colleagues in the American Journal of Physiology — Endocrinology and Metabolism demonstrated in L6 myotubes and muscle-specific aPKC-knockout mice that AICAR and metformin both increase muscle glucose transport through AMPK-, ERK-, and PDK1-dependent activation of atypical PKC — a cascade not required for treadmill-exercise-stimulated glucose uptake, indicating the pharmacologic and physiologic routes to GLUT4 activation are mechanistically distinct. A 2018 study by Hall, Griss, and colleagues in EMBO Molecular Medicine found that AICAR, but not metformin, prevented inflammation-associated muscle wasting in the C26 cancer-cachexia and endotoxin-sepsis mouse models; AICAR's anti-atrophic effect was reproduced by the specific AMPK activator A-769662 and blocked by Compound C, while metformin — a mitochondrial Complex I inhibitor that promotes a glycolytic shift — was not protective, illustrating further mechanistic divergence between AMPK activators. A 2023 review by Steinberg and Hardie in Nature Reviews Molecular Cell Biology situates these findings within the broader landscape of AMPK as a therapeutic target, noting both the promise of its metabolic effects and the challenge of achieving pathway selectivity.

What Clinical Trials Have Found

Cardioprotection in CABG surgery (the human evidence base)

AICAR's only substantial human trial data comes from cardiovascular medicine, not from performance or metabolic applications. The original clinical rationale was adenosine regulation during myocardial ischemia. A 1992 study by Bolling and colleagues in the Annals of Thoracic Surgery provided the preclinical cardioprotection rationale, showing that acadesine improves postischemic cardiac recovery. An early multicenter randomized, double-blind, placebo-controlled trial by Leung, Stanley, and colleagues published in Anesthesia and Analgesia in 1994 randomized 116 CABG patients across three arms (placebo, low-dose, and high-dose acadesine) delivered as a 7-hour intravenous infusion plus cardioplegia-delivered drug; transesophageal-echocardiographic prebypass ischemia occurred in 6% of high-dose, 15% of low-dose, and 19% of placebo patients (p = 0.22, not significant), and the only notable adverse event was a mild high-dose uric acid rise of 1.6 ± 0.2 mg/dL with no clinical sequelae — a signal-generating study that did not meet its ischemia endpoints on its own but set the stage for the larger pooled analysis. A 1997 JAMA meta-analysis by Mangano pooled five international randomized, placebo-controlled trials of acadesine across 81 medical centers in 4,043 patients undergoing CABG (2,012 acadesine, 2,031 placebo) and reported a 27% reduction in perioperative myocardial infarction (odds ratio 0.69; 95% CI 0.51–0.95; p = 0.02), a 50% reduction in early cardiac death (OR 0.52; 95% CI 0.27–0.98; p = 0.04), and a 26% reduction in the combined outcome of MI, stroke, or cardiac death (OR 0.73; 95% CI 0.57–0.93; p = 0.01), with no significant effect on stroke alone. A 2006 follow-up analysis by Mangano, Miao, Tudor, and Dietzel in the Journal of the American College of Cardiology pooled 2,698 CABG patients (1,352 acadesine via intravenous 0.1 mg/kg/min for 7 hours plus 5 microg/mL in cardioplegia; 1,346 placebo) across 54 institutions and reported that, among the 100 patients who developed a perioperative myocardial infarction, 2-year mortality fell from 27.8% (15/54) on placebo to 6.5% (3/46) on acadesine (p = 0.006) — a post-hoc subgroup finding limited to the MI subpopulation rather than a primary endpoint in the overall trial. A 1999 review by Nawarskas in Heart Disease summarized the cardioprotective rationale and the state of development before the Phase 3 failure. Neither the individual trials nor the meta-analysis produced results sufficient for FDA approval, and a 2008 regulatory development history published in Drugs in R&D documented the full Phase 3 regulatory outcome, confirming that acadesine failed to receive approval after the CABG program.

Oncology trials in chronic lymphocytic leukemia

A second wave of human trials emerged after researchers identified AMPK-independent pro-apoptotic activity of AICAR in B-cell chronic lymphocytic leukemia (CLL). A 2003 study by Campàs and colleagues in Blood demonstrated that acadesine activates AMPK and induces apoptosis selectively in B-CLL cells but not T lymphocytes, establishing the rationale for hematologic trials. A 2010 study by Santidrián and colleagues, also in Blood, further characterized the apoptotic mechanism as involving BIM and NOXA upregulation independently of both AMPK and p53, providing mechanistic complexity and flagging off-target effects relevant to the safety profile. A Phase I/II multicenter open-label trial by Van Den Neste, Cazin, Janssens, and colleagues, published in Cancer Chemotherapy and Pharmacology in 2013, evaluated acadesine in 24 patients with relapsed or refractory B-cell CLL (18 in Part I dose-escalation 50–315 mg/kg; 6 in Part II at 210 mg/kg), establishing a maximum tolerated dose of 210 mg/kg with a manageable safety profile — although grade ≥2 hyperuricemia was common and required prophylactic allopurinol. Observed trends included reductions in peripheral CLL cell counts and lymphadenopathy in some participants, but the small cohort limits any efficacy conclusions. The program was subsequently abandoned. A 2010 expert review by Van Den Neste, Van den Berghe, and Bontemps in Expert Opinion on Investigational Drugs summarizes the repurposing rationale and its limitations. As of April 2026, no human trial data for AICAR in endurance, exercise performance, or metabolic optimization has been published.

What the absence of performance trials means

The gap between the compelling 2008 mouse data and the absence of human performance trials is not accidental. WADA's 2009 prohibition removed much of the incentive for academic or commercial development of AICAR for athletic applications. The compound's pharmacological profile — including off-target effects identified in a 2014 PNAS study by Liu and colleagues showing that AICAR blocks cell-cycle progression through proteasomal degradation of the G2M phosphatase cdc25c — independently of AMPK — while a direct AMPK activator (A769662) produced no antiproliferative effect, uncoupling AMPK activation from the cell-cycle arrest historically attributed to it — and a key limitation identified by Dolinar and colleagues in 2018 in the American Journal of Physiology: Cell Physiology, showing that endogenous nucleosides can block AICAR-stimulated AMPK activation, further complicated its development pathway. The result is a compound with mechanistically rich preclinical science and almost no human efficacy data for the applications that drive most consumer interest in it.

How AICAR Compares to Other AMPK Activators

AICAR is one of several compounds that activate AMPK, but its mechanism differs from the others in ways that matter for understanding both its effects and its limitations.

Metformin, the most widely prescribed diabetes medication, activates AMPK indirectly by inhibiting Complex I of the mitochondrial respiratory chain, reducing ATP production and raising the AMP-to-ATP ratio through genuine energetic stress. AICAR bypasses this step by delivering a direct AMP mimic (ZMP) without altering actual energy status. As Sajan and colleagues demonstrated in 2010, the two compounds produce similar glucose transport outcomes in muscle but through distinct downstream signaling involving AMPK, ERK, PDK1, and atypical PKC, meaning they are mechanistically parallel, not identical. Metformin has extensive human clinical data and FDA approval for type 2 diabetes; AICAR does not.

SLU-PP-332 is a more recent exercise mimetic candidate that operates through a different pathway: pan-agonism of estrogen-related receptors (ERRα, ERRβ, ERRγ), the transcription factors that exercise activates upstream of mitochondrial biogenesis programs. Where AICAR acts through AMPK as an energy-sensing signal, SLU-PP-332 acts at the nuclear receptor level that AMPK ultimately feeds into. SLU-PP-332 has no human data and no IND; it is a preclinical research compound at an earlier stage than even AICAR's limited human trial history.

A 2018 review by Weihrauch and Handschin in Biochemical Pharmacology and a 2016 review by Wall, Yu, Atkins, Downes, and Evans in the Journal of Molecular Endocrinology both address the broader class of exercise mimetics, including AICAR, and reach a consistent conclusion: pharmacological replication of exercise is mechanistically plausible at the molecular level but has not been validated in humans, and each intervention in the pathway carries its own specificity limitations and unknown long-term safety profile.

Side Effects and Safety Considerations

Human safety data for AICAR comes primarily from the CABG cardioprotection trials and the CLL oncology program, neither of which is directly applicable to the doses or populations relevant to performance use.

From the CABG and CLL trial records, the most consistently reported adverse events include:

• Hyperuricemia (elevated uric acid), attributed to nucleoside metabolism and consistent with AICAR's purine precursor structure.
• Hypoglycemia risk in fasted or metabolically sensitive individuals, consistent with AICAR's AMPK-mediated enhancement of glucose uptake.
• Gastrointestinal discomfort, reported in oncology trial participants at therapeutic doses.
• Potential for off-target AMPK-independent effects on cell-cycle regulation, as Liu and colleagues characterized in a 2014 PNAS paper showing AICAR blocks the G2M phosphatase cdc25c via proteasomal degradation even when AMPK is not activated.
• Nucleoside-mediated blockade of AICAR's own AMPK activity at higher endogenous nucleoside concentrations, limiting predictable dose-response relationships.

A 2017 review by Guerrieri, Moon, and van Praag in Brain Plasticity contextualizes AICAR within the exercise-mimetic literature and notes that systemic AMPK activation, while metabolically favorable in preclinical models, carries theoretical risks in rapidly dividing tissues, given AMPK's role in cell cycle regulation. Long-term human safety data for doses and durations relevant to fitness applications does not exist. A 2021 critical review by Hawley, Joyner, and Green in the Journal of Physiology argues that the physiological complexity of exercise adaptations, which involve mechanical, neural, cardiovascular, and metabolic signals simultaneously, makes pharmacological substitution with any single compound biologically reductive.

Who Should Not Use AICAR

AICAR has no approved indication and no legitimate prescription pathway for performance use. Based on its pharmacology and the trial populations in which it has been evaluated, the following groups carry elevated theoretical risk from any exposure:

• Individuals with a history of hyperuricemia or gout — AICAR's purine nucleoside structure increases uric acid burden.
• Individuals prone to hypoglycemia, including those fasted, on insulin, or on sulfonylureas — AICAR enhances GLUT4-mediated glucose uptake independent of insulin.
• Individuals with active or suspected malignancy — AICAR's AMPK-independent effects on BIM, NOXA, mTOR, and the cell cycle are not characterized for safe exposure outside a research context.
• Pregnant or breastfeeding individuals — no safety data exist.
• Competitive athletes subject to WADA jurisdiction — AICAR is prohibited in- and out-of-competition.
• Anyone considering gray-market material sold as a research chemical — identity, purity, and dose cannot be verified.

AICAR and Anti-Doping: WADA Status

As of the 2026 WADA Prohibited List, AICAR is classified as a prohibited substance under category S4.5 (Hormone and Metabolic Modulators). The prohibition has been in continuous effect since 2009, directly following the publication of Narkar and colleagues' 2008 Cell paper demonstrating endurance enhancement in mice.

WADA's prohibition preceded the development of reliable detection methodology, which required creating tests that could distinguish exogenously administered AICAR from endogenous AICA-ribonucleotide, a natural intermediate in purine biosynthesis. A 2014 study by Piper and colleagues in Rapid Communications in Mass Spectrometry described a carbon isotope ratio method for determining whether urinary AICAR is of endogenous or exogenous origin. A 2019 study by Sobolevsky and Ahrens in Drug Testing and Analysis characterized urinary AICAR and mannitol concentrations in an athlete population to establish baseline reference ranges. A 2022 study by Sobolevsky and colleagues in the same journal further refined detection by establishing the AICAR-to-SAICAR ratio as an additional exogenous-use marker. A 2016 review by Thevis and Schänzer in Rapid Communications in Mass Spectrometry placed AICAR within the broader anti-doping challenge of performance-modifying compounds affecting skeletal muscle function and mitochondrial biogenesis. Cross-species concerns have also been studied; a 2017 doping control analysis by Wong and colleagues in Drug Testing and Analysis examined AICAR in equine urine and plasma following administration.

For competitive athletes subject to WADA regulations, any detectable exogenous AICAR constitutes a doping violation regardless of intent or source. The prohibition applies in-competition and out-of-competition.

Approval Status and What Comes Next

As of April 2026, AICAR has no FDA-approved indication for any use. The CABG cardioprotection program that represented its most advanced clinical development was completed in the 1990s and did not result in approval. The CLL oncology program reached Phase I/II before being abandoned. No active Investigational New Drug (IND) application for AICAR in metabolic disease, exercise performance, or any other indication is publicly registered as of April 2026.

Whether any future development pathway exists for AICAR in a therapeutic context is unknown. The compound's WADA prohibition creates a practical barrier to any clinical development program that would involve athletic or exercise populations. Its complex pharmacology — including the nucleoside-interference limitation, off-target cell cycle effects, and narrow therapeutic window suggested by animal data — presents formulation and dosing challenges. The AMPK pathway itself remains an active target for drug development, with newer, more selective activators being designed to address the specificity problems that AICAR's mechanism inherits from its AMP-mimetic approach. For anyone interested in the metabolic biology AICAR activates, the research value is substantial; for anyone seeking a currently available therapeutic application, none exists.

Understanding Your Metabolic Baseline

Whether or not AICAR or any other AMPK-targeting compound eventually finds a therapeutic application, the metabolic markers its mechanism addresses are measurable today. AMPK's downstream targets map directly onto biomarkers that reflect insulin sensitivity, glucose regulation, lipid metabolism, and mitochondrial function. Fasting insulin and fasting glucose capture the state of glucose homeostasis that AMPK activation improves in preclinical models. HbA1c reflects average glucose exposure over 90 days and provides a longer-term metabolic context. Triglycerides respond to the fat oxidation pathways that AMPK governs; the triglyceride-to-HDL ratio is one of the more sensitive metabolic risk signals in standard bloodwork. Uric acid, which rises as a byproduct of purine metabolism, may be influenced by AICAR's nucleoside pharmacology and is an independent cardiovascular and metabolic risk marker. A lipid panel including HDL, LDL, and triglycerides rounds out the metabolic picture. These markers can be tracked through Superpower's blood sugar and insulin sensitivity biomarker guide, which covers the core panel relevant to metabolic health monitoring. The metabolic health and weight loss biomarker guide covers additional markers in this context.

That principle — understanding your metabolic baseline in detail before drawing conclusions about any intervention — is central to Superpower's approach to preventive health. The compounds under investigation will continue to evolve. The value of knowing precisely where your metabolic markers stand will not.

IMPORTANT SAFETY INFORMATION

AICAR (acadesine) is not FDA-approved for any indication. Superpower Health does not prescribe, sell, compound, or facilitate access to AICAR. This article is provided for educational and informational purposes only and does not constitute medical advice. Any use of AICAR outside of an approved clinical trial is investigational and lacks established safety data in the context of fitness, metabolic optimization, or endurance enhancement.

Contraindications and risk factors (from clinical trial records): hyperuricemia or gout history (AICAR metabolism increases uric acid burden); hypoglycemia risk in fasted or insulin-sensitive individuals (AICAR-driven AMPK activation increases GLUT4-mediated glucose uptake); known hypersensitivity to adenosine analogs or nucleoside compounds. These contraindications are derived from trial populations not representative of healthy athletes or performance users; the full contraindication profile for non-clinical use is not established.

Warnings: long-term human safety data do not exist for fitness-relevant doses or durations; off-target cell cycle effects have been identified in preclinical models; endogenous nucleosides may block AICAR-stimulated AMPK activation, creating unpredictable pharmacodynamics; gray-market material sold as a research chemical is uncontrolled for purity, sterility, or dose accuracy.

Common adverse events from clinical trials: hyperuricemia; hypoglycemia risk; gastrointestinal discomfort.

Anti-doping status: As of the 2026 WADA Prohibited List, AICAR is classified as a prohibited substance under S4.5 (Hormone and Metabolic Modulators), prohibited both in-competition and out-of-competition. Athletes subject to WADA jurisdiction should be aware that detectable exogenous AICAR constitutes a doping violation regardless of source or intent.

As of April 2026, no active IND for AICAR in metabolic, endurance, or performance indications is publicly registered. No completed human efficacy trials for fitness applications have been published. Full FDA-approved prescribing information does not exist; compound reference data available at PubChem (CID 378611).

Additional Questions

How does AICAR compare to metformin?

Both compounds activate AMPK, but through different mechanisms. Metformin inhibits mitochondrial Complex I, creating genuine energetic stress that raises the AMP-to-ATP ratio and activates AMPK indirectly. AICAR delivers ZMP, an AMP mimic, directly, activating AMPK without altering actual energy status. A 2010 study by Sajan and colleagues found that both compounds increase muscle glucose transport through distinct AMPK-, ERK-, and PDK1-dependent downstream pathways converging on atypical PKC. Metformin has extensive human clinical data and FDA approval for type 2 diabetes; AICAR does not.

Is AICAR safe for human use?

Human safety data for AICAR comes from CABG cardioprotection trials in the 1990s and a CLL Phase I/II oncology program in the 2000s. Reported adverse events in those contexts included hyperuricemia, hypoglycemia risk, and gastrointestinal discomfort. Long-term safety data at doses relevant to fitness use does not exist. Off-target effects on cell cycle regulation and theoretical risks from systemic AMPK activation in proliferating tissues have been identified in preclinical research. No safety profile for AICAR as a performance compound in humans has been established.

What biomarkers should I monitor for metabolic health relevant to AMPK signaling?

The core metabolic markers that reflect AMPK's downstream territory include fasting insulin, fasting glucose, HbA1c, triglycerides, HDL cholesterol, and the triglyceride-to-HDL ratio. Uric acid is an additional marker with relevance to purine metabolism and cardiometabolic risk. These markers provide a baseline for understanding insulin sensitivity, fat metabolism, and glucose regulation. Superpower's blood sugar and insulin sensitivity biomarker guide covers interpretation of these values in the context of metabolic health.